Bruker (NASDAQ:BRKR) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Key Points

• Bruker beat Q1 expectations with non‑GAAP EPS of $0.31 (vs. ~$0.23 estimate) and revenue of $823.4M, and management reconfirmed FY‑2026 guidance of $3.57B–$3.60B revenue and $2.10–$2.15 non‑GAAP EPS, though organic revenue was down about 4.4% year‑over‑year.
• Order momentum improved—BSI organic bookings grew in the high single digits with book‑to‑bill >1 for a third consecutive quarter—and management expects a return to organic revenue growth in Q2, supported by AI‑driven franchises like semi‑metrology, SciY lab‑digitization, security detection and large BEST superconductor orders.
• Margins were pressured in Q1 (non‑GAAP gross margin 50%, operating margin 10.2%, and a slightly negative net margin), but the company targets a 250–300 bp non‑GAAP operating margin expansion in 2026 driven by roughly $140M of annualized cost savings, while flagging execution and macro risks.

Bruker (NASDAQ:BRKR - Get Free Report) released its earnings results on Wednesday. The medical research company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08, FiscalAI reports. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $796.11 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker's conference call:

• Q1 results beat expectations with reported revenue of $823.4M (+2.7% reported, organic -4.4%) and non‑GAAP EPS of $0.31, and management reconfirmed full‑year guidance of $3.57B–$3.60B revenue and $2.10–$2.15 non‑GAAP EPS.
• Order momentum strengthened—BSI organic bookings grew in the high single digits and book‑to‑bill stayed >1 for the third consecutive quarter—management expects a return to organic revenue growth in Q2 (low‑ to mid‑single digits).
• Several idiosyncratic, AI‑driven growth engines are accelerating performance, including semi‑metrology (now >$300M annual), SciY lab‑digitization/software (~$50M), security detection (~$70M), and large multi‑year BEST superconductor orders, which management says provide durable secular tailwinds.
• Margins were pressured in Q1 (non‑GAAP gross margin 50%, operating margin 10.2%) by FX, tariffs and mix, but management expects a 250–300 bp non‑GAAP operating margin expansion in 2026 driven by cost‑savings (now tracking ~$140M annualized), though execution and macro risks remain.

Bruker Stock Up 11.2%

BRKR traded up $4.27 on Wednesday, hitting $42.28. 2,191,004 shares of the company were exchanged, compared to its average volume of 2,284,570. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The stock's fifty day moving average is $37.13 and its 200-day moving average is $41.99. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22. The company has a market cap of $6.44 billion, a PE ratio of -281.89, a PEG ratio of 2.18 and a beta of 1.12.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker's payout ratio is -133.33%.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.20% of the company's stock.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently added to or reduced their stakes in BRKR. Los Angeles Capital Management LLC bought a new stake in shares of Bruker during the 4th quarter valued at approximately $26,000. Parallel Advisors LLC boosted its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company's stock valued at $41,000 after purchasing an additional 479 shares during the last quarter. Allworth Financial LP increased its position in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock worth $29,000 after buying an additional 257 shares during the period. Summit Securities Group LLC bought a new position in shares of Bruker in the 4th quarter worth about $50,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Bruker by 144.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company's stock valued at $70,000 after purchasing an additional 876 shares during the period. Institutional investors own 79.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BRKR. Weiss Ratings raised shares of Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, April 24th. The Goldman Sachs Group reduced their price objective on shares of Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research note on Friday, February 13th. Guggenheim cut their price objective on Bruker from $58.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Barclays decreased their price target on shares of Bruker from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 14th. Finally, Citigroup cut their price target on Bruker from $53.00 to $40.00 and set a "neutral" rating for the company in a report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $49.38.

More Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 beat — Bruker reported EPS of $0.31 versus the consensus ~$0.23 and revenue of $823.4M vs. ~$796.1M; revenue rose ~2.7% year‑over‑year, which supported the upside reaction. Zacks: Bruker Surpasses Q1 Earnings and Revenue Estimates
• Neutral Sentiment: FY‑2026 guidance essentially in line with expectations — management set EPS guidance of 2.10–2.15 and revenue guidance near $3.6B, which matches consensus and reduces uncertainty but doesn’t materially raise the bar. (See company press release/slide deck for details.) Bruker Press Release / Slide Deck
• Negative Sentiment: Profitability and YoY EPS compression — EPS declined from $0.47 a year ago to $0.31 this quarter and the company reported a slightly negative net margin (~‑0.25%), highlighting margin pressure that may limit upside absent margin improvement. MarketBeat: Q1 Results & Metrics
• Negative Sentiment: Investor sentiment noise — articles flagged insider selling and “earnings jitters,” which can amplify volatility even after a beat if investors worry about sustainability of improvement. Yahoo: Earnings Jitters and Insider Selling

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.